Published in Cancer Weekly, January 21st, 2003
The company reported that Reolysin appeared to be well tolerated when surgically delivered into the brain during the treatment of the first six patients.
Determination of the safety of Reolysin is the primary purpose of the phase I study. The study is examining the use of a single, intratumoral injection of Reolysin delivered using imaging-guided surgery, in patients with malignant glioma that has recurred...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.